MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Avutometinib

CAS No. : 946128-88-7

MCE 站：Avutometinib

产品活性：Avutometinib (Ro 5126766) 是一种有效的双重 MEK/RAF 抑制剂，抑制 BRAF^V600E，CRAF, MEK，和 BRAF，IC₅₀ 分别为 8.2 nM, 56 nM, 160 nM 和 190 nM。

研究领域：MAPK/ERK Pathway

作用靶点：MEK  |  Raf

In Vitro: Avutometinib (Ro 5126766) is an allosteric inhibitor that binds directly to MEK ａnd prevents its phosphorylation by RAF through the formation of a stable RAF-MEK complex. Ro 5126766 inhibits both the phosphorylation of MEK by RAF ａnd the activation of ERK by MEK. In cell-free MEK ａnd RAF kinase assays, Avutometinib effectively inhibits activation of ERK2 by MEK1 with an IC₅₀ of 160 nM (SD=±0.043) ａnd inhibits the phosphorylation of MEK1 protein by BRAF (IC₅₀=190 nM, SD=±0.003), BRAF^V600E (IC₅₀=8.2 nM, SD=±0.0015), ａnd CRAF (IC₅₀=56 nM, SD=±0.016). Avutometinib effectively inhibits both MEK ａnd ERK phosphorylation in a panel of human tumor cell lines including KRAS/HRAS ａnd BRAF mutant cell lines ａnd KRAS/HRAS ａnd BRAF wild-type cells. In order to investigate whether the mevalonate pathway affects the sensitivity to MEK inhibitors, human breast cancer MDA-MB-231 cells harboring KRAS ａnd BRAF mutations are treated Avutometinib, with or without statins, which inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway. The combined treatment of Avutometinib with XU 62-320 demonstrates more significant reduction in cell growth in a dose-dependent manner than the single treatment of Avutometinib. The marked combined effects of Avutometinib at 40 nM ａnd XU 62-320 at 0.3 μM is also confirmed on the suppression of the colony formation of the cells.

In Vivo: In KRAS-mutant xenograft models, Avutometinib (Ro 5126766) inhibits growth ａnd causes tumor regressions more effectively than another allosteric MEK inhibitor, PD0325901. Preclinical data from a series of human tumor mouse xenograft models indicates an ED₅₀ for Ro 5126766 of 0.03 to 0.23 mg/kg ａnd an ED₉₀ of 0.15 to 1.56 mg/kg. These effective doses are associated with target trough concentrations of 17 to 133 ng/L ａnd 87 to 901 ng/mL, respectively. . In this experiment, Avutometinib or PD0325901 is administrated at their maximum tolerated dose (MTD) in the HCT116 model (1.5 ａnd 25 mg/kg, respectively). These doses inhibit pERK ａnd ERK signaling output at similar degrees in the tumors from the drug-treated mice at 4 hours from the first drug administration. Moreover, in HCT116 models, the ED₅₀ for Avutometinib ａnd PD0325901 are 0.056 ａnd 0.80 mg/kg, respectively. Therefore, the doses used for this experiment are 26.8- ａnd 31.3-fold higher doses than the 50% effective doses, respectively. Daily oral administration of either drug causes significant tumor regression of each these tumors. However, whereas inhibition of tumor growth is maintained for the entire 28-day treatment period in Avutometinib-treated mice, tumor models receiving PD0325901 become refractory after 10 days of treatment.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Serine/Threonine Kinase Inhibitor Library  |  B-Raf IN 2  |  Sorafenib-d₄  |  AZ 628  |  B-Raf IN 7  |  Cobimetinib racemate  |  (E/Z)-Zeatin  |  Antitumor agent-60  |  Trametinib (DMSO solvate)  |  Sorafenib Tosylate  |  B-Raf IN 16  |  Dabrafenib Mesylate  |  SB-682330A  |  PD184161  |  Belvarafenib TFA  |  MEK-IN-6  |  GW284543 hydrochloride  |  L-779450  |  BI-847325  |  Hypothemycin  |  B-Raf IN 9  |  Debromohymenialdisine  |  Raf inhibitor 1  |  TBAP-001  |  RRD-251  |  BI-882370  |  Encorafenib-¹³C,d₃  |  PLX-4720  |  RGB-286638

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。